{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:50:13Z","timestamp":1772171413582,"version":"3.50.1"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Objective Development of computational approaches and tools to effectively integrate multidomain data is urgently needed for the development of newly targeted cancer therapeutics.<\/jats:p><jats:p>Methods We proposed an integrative network-based infrastructure to identify new druggable targets and anticancer indications for existing drugs through targeting significantly mutated genes (SMGs) discovered in the human cancer genomes. The underlying assumption is that a drug would have a high potential for anticancer indication if its up-\/down-regulated genes from the Connectivity Map tended to be SMGs or their neighbors in the human protein interaction network.<\/jats:p><jats:p>Results We assembled and curated 693 SMGs in 29 cancer types and found 121 proteins currently targeted by known anticancer or noncancer (repurposed) drugs. We found that the approved or experimental cancer drugs could potentially target these SMGs in 33.3% of the mutated cancer samples, and this number increased to 68.0% by drug repositioning through surveying exome-sequencing data in approximately 5000 normal-tumor pairs from The Cancer Genome Atlas. Furthermore, we identified 284 potential new indications connecting 28 cancer types and 48 existing drugs (adjusted P\u2009&amp;lt;\u2009.05), with a 66.7% success rate validated by literature data. Several existing drugs (e.g., niclosamide, valproic acid, captopril, and resveratrol) were predicted to have potential indications for multiple cancer types. Finally, we used integrative analysis to showcase a potential mechanism-of-action for resveratrol in breast and lung cancer treatment whereby it targets several SMGs (ARNTL, ASPM, CTTN, EIF4G1, FOXP1, and STIP1).<\/jats:p><jats:p>Conclusions In summary, we demonstrated that our integrative network-based infrastructure is a promising strategy to identify potential druggable targets and uncover new indications for existing drugs to speed up molecularly targeted cancer therapeutics.<\/jats:p>","DOI":"10.1093\/jamia\/ocw007","type":"journal-article","created":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:18:52Z","timestamp":1459297132000},"page":"681-691","source":"Crossref","is-referenced-by-count":51,"title":["A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes"],"prefix":"10.1093","volume":"23","author":[{"given":"Feixiong","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Fooksa","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA"},{"name":"Chemical and Physical Biology Program, Vanderbilt University School of Medicine, Nashville, TN 37232, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongming","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA"},{"name":"Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA"},{"name":"Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA"},{"name":"Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,3,28]]},"reference":[{"issue":"3","key":"2020110612370278400_ocw007-B1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov."},{"issue":"8","key":"2020110612370278400_ocw007-B2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat Genet."},{"key":"2020110612370278400_ocw007-B3","article-title":"Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes","author":"Cheng","year":"2015","journal-title":"Brief Bioinform."},{"issue":"9","key":"2020110612370278400_ocw007-B4","doi-asserted-by":"crossref","first-page":"e1004497","DOI":"10.1371\/journal.pcbi.1004497","article-title":"A gene gravity model for the evolution of cancer genomes: a study of 3,000 cancer genomes across 9 cancer types","volume":"11","author":"Cheng","year":"2015","journal-title":"PLoS Comput Biol."},{"issue":"10","key":"2020110612370278400_ocw007-B5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s13059-014-0489-9","article-title":"MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis","volume":"15","author":"Jia","year":"2014","journal-title":"Genome Biol."},{"issue":"7471","key":"2020110612370278400_ocw007-B6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature."},{"key":"2020110612370278400_ocw007-B7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1755-8794-7-11","article-title":"Patterns and processes of somatic mutations in nine major cancers","volume":"7","author":"Jia","year":"2014","journal-title":"BMC Med Genomics."},{"issue":"10","key":"2020110612370278400_ocw007-B8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13073-014-0081-7","article-title":"Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach","volume":"6","author":"Vuong","year":"2014","journal-title":"Genome Med."},{"issue":"12","key":"2020110612370278400_ocw007-B9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nmeth.2689","article-title":"DGIdb: mining the druggable genome","volume":"10","author":"Griffith","year":"2013","journal-title":"Nat Methods."},{"issue":"5","key":"2020110612370278400_ocw007-B10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1056\/NEJMra072367","article-title":"Oncogenes and cancer","volume":"358","author":"Croce","year":"2008","journal-title":"N Engl J Med."},{"issue":"3","key":"2020110612370278400_ocw007-B11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ccell.2015.02.007","article-title":"In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities","volume":"27","author":"Rubio-Perez","year":"2015","journal-title":"Cancer Cell."},{"issue":"8","key":"2020110612370278400_ocw007-B12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med."},{"issue":"7514","key":"2020110612370278400_ocw007-B13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature13387","article-title":"A vaccine targeting mutant IDH1 induces antitumour immunity","volume":"512","author":"Schumacher","year":"2014","journal-title":"Nature."},{"issue":"11","key":"2020110612370278400_ocw007-B14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat Rev Drug Discov."},{"issue":"11","key":"2020110612370278400_ocw007-B15","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.18632\/oncotarget.1984","article-title":"Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy","volume":"5","author":"Cheng","year":"2014","journal-title":"Oncotarget."},{"issue":"3","key":"2020110612370278400_ocw007-B16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nrd4201","article-title":"Targeting tumour-supportive cellular machineries in anticancer drug development","volume":"13","author":"Dobbelstein","year":"2014","journal-title":"Nat Rev Drug Discov."},{"issue":"7492","key":"2020110612370278400_ocw007-B17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature."},{"issue":"7418","key":"2020110612370278400_ocw007-B18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Research Network","year":"2012","journal-title":"Nature."},{"issue":"7484","key":"2020110612370278400_ocw007-B19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature."},{"issue":"7407","key":"2020110612370278400_ocw007-B20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas Research Network","year":"2012","journal-title":"Nature."},{"issue":"2","key":"2020110612370278400_ocw007-B21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell."},{"issue":"6046","key":"2020110612370278400_ocw007-B22","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science."},{"issue":"7456","key":"2020110612370278400_ocw007-B23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature."},{"issue":"22","key":"2020110612370278400_ocw007-B24","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med."},{"issue":"6","key":"2020110612370278400_ocw007-B25","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","article-title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers","volume":"150","author":"Govindan","year":"2012","journal-title":"Cell."},{"issue":"7417","key":"2020110612370278400_ocw007-B26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"Cancer Genome Atlas Research Network","year":"2012","journal-title":"Nature."},{"issue":"7353","key":"2020110612370278400_ocw007-B27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature."},{"issue":"7447","key":"2020110612370278400_ocw007-B28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature."},{"issue":"6","key":"2020110612370278400_ocw007-B29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/ng.2983","article-title":"Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer","volume":"46","author":"Wang","year":"2014","journal-title":"Nat Genet."},{"issue":"Database issue","key":"2020110612370278400_ocw007-B30","first-page":"D8","article-title":"Database resources of the National Center for Biotechnology Information","volume":"41","author":"Corrdinators","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"2020110612370278400_ocw007-B31","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/molbev\/msu167","article-title":"Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome","volume":"31","author":"Cheng","year":"2014","journal-title":"Mol Biol Evol."},{"key":"2020110612370278400_ocw007-B32","article-title":"ccmGDB: a database for cancer cell metabolism genes","author":"Kim","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"2020110612370278400_ocw007-B33","doi-asserted-by":"crossref","first-page":"D1128","DOI":"10.1093\/nar\/gkr797","article-title":"Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery","volume":"40","author":"Zhu","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"2020110612370278400_ocw007-B34","doi-asserted-by":"crossref","first-page":"D1035","DOI":"10.1093\/nar\/gkq1126","article-title":"DrugBank 3.0: a comprehensive resource for \u2018omics\u2019 research on drugs","volume":"39","author":"Knox","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"2020110612370278400_ocw007-B35","first-page":"D913","article-title":"The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge","volume":"36","author":"Hernandez-Boussard","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"2020110612370278400_ocw007-B36","doi-asserted-by":"crossref","first-page":"e1002503","DOI":"10.1371\/journal.pcbi.1002503","article-title":"Prediction of drug-target interactions and drug repositioning via network-based inference","volume":"8","author":"Cheng","year":"2012","journal-title":"PLoS Comput Biol."},{"issue":"4","key":"2020110612370278400_ocw007-B37","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1021\/ci400010x","article-title":"Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space","volume":"53","author":"Cheng","year":"2013","journal-title":"J Chem Inf Model."},{"issue":"e2","key":"2020110612370278400_ocw007-B38","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1136\/amiajnl-2013-002512","article-title":"Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties","volume":"21","author":"Cheng","year":"2014","journal-title":"J Am Med Inform Assoc."},{"issue":"Database issue","key":"2020110612370278400_ocw007-B39","doi-asserted-by":"crossref","first-page":"D267","DOI":"10.1093\/nar\/gkh061","article-title":"The Unified Medical Language System (UMLS): integrating biomedical terminology","volume":"32","author":"Bodenreider","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"5795","key":"2020110612370278400_ocw007-B40","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science."},{"issue":"1","key":"2020110612370278400_ocw007-B41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Roy Statist Soc Ser B."},{"issue":"4","key":"2020110612370278400_ocw007-B42","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.cell.2013.10.011","article-title":"Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome","volume":"155","author":"Davoli","year":"2013","journal-title":"Cell."},{"issue":"2","key":"2020110612370278400_ocw007-B43","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1074\/mcp.M115.053199","article-title":"Systematic prioritization of druggable mutations in \u223c5,000 genomes across 16 cancer types using a structural genomics-based approach","volume":"15","author":"Zhao","year":"2016","journal-title":"Mol Cell Proteomics."},{"issue":"8","key":"2020110612370278400_ocw007-B44","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med."},{"issue":"11","key":"2020110612370278400_ocw007-B45","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"issue":"11","key":"2020110612370278400_ocw007-B46","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat Chem Biol."},{"issue":"2","key":"2020110612370278400_ocw007-B47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrc2787","article-title":"Targeting the cancer kinome through polypharmacology","volume":"10","author":"Knight","year":"2010","journal-title":"Nat Rev Cancer."},{"issue":"25","key":"2020110612370278400_ocw007-B48","doi-asserted-by":"crossref","first-page":"E3216","DOI":"10.1073\/pnas.1420811112","article-title":"TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth","volume":"112","author":"Haricharan","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5","key":"2020110612370278400_ocw007-B49","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jpain.2012.02.005","article-title":"+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats","volume":"13","author":"Lewis","year":"2012","journal-title":"J Pain."},{"issue":"6","key":"2020110612370278400_ocw007-B50","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4161\/chan.2.6.7362","article-title":"Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine","volume":"2","author":"Rajamani","year":"2008","journal-title":"Channels (Austin)."},{"issue":"4","key":"2020110612370278400_ocw007-B51","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/17425255.4.4.493","article-title":"Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety","volume":"4","author":"Kothare","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"10","key":"2020110612370278400_ocw007-B52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1089\/thy.2013.0057","article-title":"Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation","volume":"23","author":"Kim","year":"2013","journal-title":"Thyroid."},{"issue":"5185","key":"2020110612370278400_ocw007-B53","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/2211016a0","article-title":"Mechanism of action of reagents that uncouple oxidative phosphorylation","volume":"221","author":"Weinbach","year":"1969","journal-title":"Nature."},{"issue":"12","key":"2020110612370278400_ocw007-B54","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1158\/0008-5472.CAN-10-3978","article-title":"Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations","volume":"71","author":"Osada","year":"2011","journal-title":"Cancer Res."},{"issue":"15","key":"2020110612370278400_ocw007-B55","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/1078-0432.CCR-12-2895","article-title":"Anticancer effects of niclosamide in human glioblastoma","volume":"19","author":"Wieland","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"13","key":"2020110612370278400_ocw007-B56","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","article-title":"The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2","volume":"22","author":"Kramer","year":"2003","journal-title":"EMBO J."},{"issue":"8","key":"2020110612370278400_ocw007-B57","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/00002030-200405210-00003","article-title":"Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression","volume":"18","author":"Ylisastigui","year":"2004","journal-title":"AIDS."},{"issue":"2","key":"2020110612370278400_ocw007-B58","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.lungcan.2013.08.010","article-title":"Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines","volume":"82","author":"Shirsath","year":"2013","journal-title":"Lung Cancer."},{"key":"2020110612370278400_ocw007-B59","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1196\/annals.1414.011","article-title":"Captopril as a potential inhibitor of lung tumor growth and metastasis","volume":"1138","author":"Attoub","year":"2008","journal-title":"Ann N Y Acad Sci."},{"issue":"5297","key":"2020110612370278400_ocw007-B60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.275.5297.218","article-title":"Cancer chemopreventive activity of resveratrol, a natural product derived from grapes","volume":"275","author":"Jang","year":"1997","journal-title":"Science."},{"issue":"17-18","key":"2020110612370278400_ocw007-B61","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.drudis.2010.07.005","article-title":"Resveratrol and derivatives for the prevention and treatment of cancer","volume":"15","author":"Fulda","year":"2010","journal-title":"Drug Discov Today."},{"issue":"24","key":"2020110612370278400_ocw007-B62","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1158\/1078-0432.CCR-10-1486","article-title":"Resveratrol: challenges in translation to the clinic\u2013a critical discussion","volume":"16","author":"Subramanian","year":"2010","journal-title":"Clin Cancer Res."},{"key":"2020110612370278400_ocw007-B63","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.1038\/cddis.2014.9","article-title":"DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information","volume":"5","author":"Amelio","year":"2014","journal-title":"Cell Death Dis."},{"issue":"13","key":"2020110612370278400_ocw007-B64","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1158\/0008-5472.CAN-11-0608","article-title":"MicroRNA sequence and expression analysis in breast tumors by deep sequencing","volume":"71","author":"Farazi","year":"2011","journal-title":"Cancer Res."},{"issue":"38","key":"2020110612370278400_ocw007-B65","doi-asserted-by":"crossref","first-page":"13550","DOI":"10.1073\/pnas.0506230102","article-title":"An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival","volume":"102","author":"Miller","year":"2005","journal-title":"Proc Natl Acad Sci USA."},{"issue":"25","key":"2020110612370278400_ocw007-B66","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N Engl J Med."},{"issue":"46","key":"2020110612370278400_ocw007-B67","doi-asserted-by":"crossref","first-page":"18767","DOI":"10.1073\/pnas.1203853109","article-title":"DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs","volume":"109","author":"Badura","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"issue":"6","key":"2020110612370278400_ocw007-B68","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/mnfr.200700325","article-title":"Resveratrol inhibits migration and invasion of human breast-cancer cells","volume":"52","author":"Tang","year":"2008","journal-title":"Mol Nutr Food Res."},{"issue":"7074","key":"2020110612370278400_ocw007-B69","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature04296","article-title":"Oncogenic pathway signatures in human cancers as a guide to targeted therapies","volume":"439","author":"Bild","year":"2006","journal-title":"Nature."},{"issue":"2","key":"2020110612370278400_ocw007-B70","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1309\/AJCPDHQFNYJZ01YG","article-title":"High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer","volume":"138","author":"Feng","year":"2012","journal-title":"Am J Clin Pathol."},{"issue":"1","key":"2020110612370278400_ocw007-B71","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1158\/1078-0432.CCR-08-1258","article-title":"An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer","volume":"15","author":"Roepman","year":"2009","journal-title":"Clin Cancer Res."},{"issue":"15","key":"2020110612370278400_ocw007-B72","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-06-1191","article-title":"Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung","volume":"66","author":"Raponi","year":"2006","journal-title":"Cancer Res."},{"issue":"5","key":"2020110612370278400_ocw007-B73","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3892\/ijo.2014.2627","article-title":"Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer","volume":"45","author":"Yeh","year":"2014","journal-title":"Int J Oncol."},{"issue":"6","key":"2020110612370278400_ocw007-B74","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.prp.2013.03.011","article-title":"Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer","volume":"209","author":"Noh","year":"2013","journal-title":"Pathol Res Pract."},{"issue":"Pt 7","key":"2020110612370278400_ocw007-B75","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1242\/jcs.093781","article-title":"Cortactin in cell migration and cancer at a glance","volume":"125","author":"MacGrath","year":"2012","journal-title":"J Cell Sci."},{"issue":"6","key":"2020110612370278400_ocw007-B76","doi-asserted-by":"crossref","first-page":"e1004202","DOI":"10.1371\/journal.pcbi.1004202","article-title":"Deciphering signaling pathway networks to understand the molecular mechanisms of metformin action","volume":"11","author":"Sun","year":"2015","journal-title":"PLoS Comput Biol."},{"issue":"2","key":"2020110612370278400_ocw007-B77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cell.2015.05.056","article-title":"Elucidating compound mechanism of action by network perturbation analysis","volume":"162","author":"Woo","year":"2015","journal-title":"Cell."},{"issue":"6168","key":"2020110612370278400_ocw007-B78","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.1248627","article-title":"Direct in\u00a0vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas","volume":"343","author":"Schramek","year":"2014","journal-title":"Science."},{"issue":"7536","key":"2020110612370278400_ocw007-B79","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14136","article-title":"Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex","volume":"517","author":"Konermann","year":"2015","journal-title":"Nature."},{"issue":"9","key":"2020110612370278400_ocw007-B80","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/bioinformatics\/btq126","article-title":"PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations","volume":"26","author":"Denny","year":"2010","journal-title":"Bioinformatics."},{"issue":"Database issue","key":"2020110612370278400_ocw007-B81","doi-asserted-by":"crossref","first-page":"D1001","DOI":"10.1093\/nar\/gkt1229","article-title":"The NHGRI GWAS Catalog, a curated resource of SNP-trait associations","volume":"42","author":"Welter","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"2020110612370278400_ocw007-B82","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nbt.2749","article-title":"Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data","volume":"31","author":"Denny","year":"2013","journal-title":"Nat Biotechnol."}],"container-title":["Journal of the American Medical Informatics Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jamia\/article\/23\/4\/681\/2199932","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jamia\/article\/23\/4\/681\/2199932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T10:26:26Z","timestamp":1718447186000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jamia\/article\/23\/4\/681\/2199932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,28]]},"references-count":82,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,3,28]]},"published-print":{"date-parts":[[2016,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jamia\/ocw007","relation":{},"ISSN":["1527-974X","1067-5027"],"issn-type":[{"value":"1527-974X","type":"electronic"},{"value":"1067-5027","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,7]]},"published":{"date-parts":[[2016,3,28]]}}}